Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?

Parihar, Robin

doi:10.1016/j.ymthe.2017.04.012

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For γδ-T cells without the limitation of HLA matching, the most abundant γδ-T cells expressed the Vγ9 Vδ2 TCR that recognizes isopentenyl pyrophosphate (IPP), which is overproduced in cancer cells. Costimulation domain-CAR γδ-T cells have been considered a safer therapy because the CAR follows only one pathway to stimulate the immune response, and the cytotoxicity was limited to the reaction induced by the IPP antigen [121,122]. Furthermore, a large expansion platform has been successfully established, which has the potential to make γδ-T cells an off-the-shelf product and a possible source of U-CAR-T cell therapy [123].…”

Section: The Sources Of T Cellsmentioning

confidence: 99%

Recent advances in CAR-T cell engineering

et al. 2020

View full text Add to dashboard Cite

Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for relapsed or refractory tumors, particularly for hematological malignancies. Although the initially approved anti-CD19 CART therapy has produced impressive outcomes, setbacks such as high relapse rates and resistance were experienced, driving the need to discover engineered CART cells that are more effective for therapeutic use. Innovations in the structure and manufacturing of CART cells have resulted in significant improvements in efficacy and persistence, particularly with the development of fourth-generation CART cells. Paired with an immune modifier, the use of fourthgeneration and next-generation CART cells will not be limited because of cytotoxic effects and will be an efficient tool for overcoming the tumor microenvironment. In this review, we summarize the recent transformations in the ectodomain, transmembrane domain, and endodomain of the CAR structure, which, together with innovative manufacturing technology and improved cell sources, improve the prospects for the future development of CART cell therapy.

show abstract

Section: The Sources Of T Cellsmentioning

confidence: 99%